Status:
COMPLETED
Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Lead Sponsor:
Pfizer
Collaborating Sponsors:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-85 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, in subjects with mild to moderate Alzheimer's disease in Japan.
Eligibility Criteria
Inclusion
- Diagnosis of mild to moderate Alzheimer's Disease
- Mini-Mental State Examination (MMSE) 16-26
Exclusion
- Significant Neurological Disease other than Alzheimer's disease
- Major psychiatric disorder
- Clinically significant systemic illness
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00959192
Start Date
August 1 2009
End Date
January 1 2013
Last Update
January 1 2016
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Tazuke Kofukai Medical Research Institute Kitano Hospital
Osaka, Osaka, Japan, 530-8480
2
Meitetsu Hospital
Aichi, Japan, 451-8511
3
Ibaraki Prefectural Central Hospital
Ibaraki, Japan, 309-1793
4
Shonan Atsugi Hospital
Kanagawa, Japan, 243-8551